Cord blood transplantation and stem cell regenerative potential

Experimental Hematology

Volumn 39, Issue 4, 2011, Pages 393-412

  Liao, Yanling ^a   Geyer, Mark B ^a   Yang, Albert J ^a   Cairo, Mitchell S ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW DEPRESSION; CELL POPULATION; CORD BLOOD STEM CELL TRANSPLANTATION; CRYOPRESERVATION; DIABETES MELLITUS; DISEASE MODEL; GRAFT VERSUS HOST REACTION; HEART INFARCTION; HEMATOLOGIC MALIGNANCY; HEMOGLOBINOPATHY; HLA SYSTEM; HUMAN; INBORN ERROR OF METABOLISM; INTERMETHOD COMPARISON; LATENT VIRUS INFECTION; MONONUCLEAR CELL; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REGENERATIVE ABILITY; REVIEW; SAFETY; SOMATIC MUTATION; TISSUE REGENERATION; TISSUE REPAIR; TREATMENT RESPONSE; VIRUS TRANSMISSION;

BLOOD BANKS; CELL DIFFERENTIATION; CELL LINEAGE; CORD BLOOD STEM CELL TRANSPLANTATION; FETAL BLOOD; HEMATOPOIETIC STEM CELLS; HUMANS; MODELS, BIOLOGICAL; REGENERATIVE MEDICINE;

ANIMALIA;

EID: 79952639189     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.01.002     Document Type: Review

References (166)

1. Gluckman E., Broxmeyer H.A., Auerbach A.D., et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989, 321:1174-1178.
2. Rocha V., Locatelli F. Searching for alternative hematopoietic stem cell donors for pediatric patients. Bone Marrow Transplant 2008, 41:207-214.
3. Trends in Allogeneic Transplants. National Marrow Donor Program; 2009.
4. Pasquini M.C., Wang Z. Current use and outcome of hematopoietic stem cell transplantation. Part I: CIBMTR summary slides. CIBMTR Newsletter 2009, 1:7-11.
5. Unrelated Donor Search Process, Step by Step 2009, National Marrow Donor Program, National Marrow Donor Program, Minneapolis, MN.
6. Wagner J.E., Kernan N.A., Steinbuch M., Broxmeyer H.E., Gluckman E. Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet 1995, 346:214-219.
7. Cairo M.S., Wagner J.E. Placental and/or umbilical cord blood: an alternative source of hematopoietic stem cells for transplantation. Blood 1997, 90:4665-4678.
8. Wagner J.E., Rosenthal J., Sweetman R., et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996, 88:795-802.
9. Kurtzberg J., Laughlin M., Graham M.L., et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996, 335:157-166.
10. Gluckman E., Rocha V., Boyer-Chammard A., et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997, 337:373-381.
11. Rubinstein P., Carrier C., Scaradavou A., et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998, 339:1565-1577.
12. Michel G., Rocha V., Chevret S., et al. Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. Blood 2003, 102:4290-4297.
13. Wall D.A., Carter S.L., Kernan N.A., et al. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience. Biol Blood Marrow Transplant 2005, 11:637-646.
14. Kurtzberg J., Prasad V.K., Carter S.L., et al. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood 2008, 112:4318-4327.
15. Eapen M., Rubinstein P., Zhang M.J., et al. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol 2006, 24:145-151.
16. Eapen M., Rubinstein P., Zhang M.J., et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007, 369:1947-1954.
17. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004, 351:2276-2285.
18. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004, 351:2265-2275.
19. Eapen M., Rocha V., Sanz G., et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010, 11:653-660.
20. Takahashi S., Ooi J., Tomonari A., et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood 2007, 109:1322-1330.
21. Kumar P., Defor T.E., Brunstein C., et al. Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival. Biol Blood Marrow Transplant 2008, 14:1394-1400.
22. Atsuta Y., Suzuki R., Nagamura-Inoue T., et al. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood 2009, 113:1631-1638.
23. Ooi J., Takahashi S., Tomonari A., et al. Unrelated cord blood transplantation after myeloablative conditioning in adults with acute myelogenous leukemia. Biol Blood Marrow Transplant 2008, 14:1341-1347.
24. Rodrigues C.A., Sanz G., Brunstein C.G., et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009, 27:256-263.
25. Majhail N.S., Weisdorf D.J., Wagner J.E., Defor T.E., Brunstein C.G., Burns L.J. Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood 2006, 107:3804-3807.
26. Yuji K., Miyakoshi S., Kato D., et al. Reduced-intensity unrelated cord blood transplantation for patients with advanced malignant lymphoma. Biol Blood Marrow Transplant 2005, 11:314-318.
27. Gluckman E., Rocha V., Ionescu I., et al. Results of unrelated cord blood transplant in fanconi anemia patients: risk factor analysis for engraftment and survival. Biol Blood Marrow Transplant 2007, 13:1073-1082.
28. Majumdar S., Robertson Z., Robinson A., Starnes S., Iyer R., Megason G. Outcome of hematopoietic cell transplantation in children with sickle cell disease, a single center's experience. Bone Marrow Transplant 2010, 45:895-900.
29. Locatelli F., Rocha V., Reed W., et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 2003, 101:2137-2143.
30. Bhatia M., Baldinger L., Billote G., et al. Preliminary results of non-ablative conditioning (NAC) with busulfan (Bu), fludarabine (Flu) and alemtuzumab followed by allogeneic stem cell transplantation (AlloSCT) to induce mixed donor chimerism in patients with sickle cell disease (SCD) [abstract]. Biol Blood Marrow Transplant 2008, 14:82-83. Abstract 221.
31. Bhatia M., Morris E., Moore V., et al. A pilot study of reduced intensity conditioning (RI) with busulfan (Bu), fludarabine (Flu), and alemtuzumab followed by allogeneic stem cell transplantation (AlloSCT) to induce sustained mixed donor chimerism in patients with symptomatic sickle cell disease (SCD). Biol Blood Marrow Transplant 2009, 15:23-24.
32. Adamkiewicz T.V., Szabolcs P., Haight A., et al. Unrelated cord blood transplantation in children with sickle cell disease: review of four-center experience. Pediatr Transplant 2007, 11:641-644.
33. Prasad V.K., Mendizabal A., Parikh S.H., et al. Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes. Blood 2008, 112:2979-2989.
34. Martin P.L., Carter S.L., Kernan N.A., et al. Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. Biol Blood Marrow Transplant 2006, 12:184-194.
35. Eapen M., Rocha V., Scaradavou A., et al. Effect of stem cell source on transplant outcomes in adults with acute leukemia: a comparison of unrelated bone marrow (BM), peripheral blood (PB) and cord blood (CB). ASH Annual Meeting Abstracts 2008, 112:151.
36. Rocha V., Wagner J.E., Sobocinski K.A., et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 2000, 342:1846-1854.
37. Laughlin M.J., Barker J., Bambach B., et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001, 344:1815-1822.
38. Gluckman E., Rocha V., Arcese W., et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol 2004, 32:397-407.
39. Cairo M.S., Wagner E.L., Fraser J., et al. Characterization of banked umbilical cord blood hematopoietic progenitor cells and lymphocyte subsets and correlation with ethnicity, birth weight, sex, and type of delivery: a Cord Blood Transplantation (COBLT) Study report. Transfusion 2005, 45:856-866.
40. Majhail N.S., Mothukuri J.M., Brunstein C.G., Weisdorf D.J. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Biol Blood Marrow Transplant 2009, 15:564-573.
41. Wagner J.E., Barker J.N., DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002, 100:1611-1618.
42. Styczynski J., Cheung Y.K., Garvin J., et al. Outcomes of unrelated cord blood transplantation in pediatric recipients. Bone Marrow Transplant 2004, 34:129-136.
43. Wagner J.E., Laughlin M., Petz L. Seventh Annual International Umbilical Cord Blood Transplantation Symposium, Los Angeles, California, June 5-6, 2009. Biol Blood Marrow Transplant 2009, 16:12-27.
44. Gluckman E. Cord blood transplantation. Biol Blood Marrow Transplant 2006, 12:808-812.
45. Barker J.N., Scaradavou A., Stevens C.E. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood 2010, 115:1843-1849.
46. Anasetti C., Hansen J.A. Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors. Transfus Sci 1994, 15:221-230.
47. Barker J.N., Davies S.M., DeFor T., Ramsay N.K., Weisdorf D.J., Wagner J.E. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 2001, 97:2957-2961.
48. van Rood J.J., Stevens C.E., Smits J., Carrier C., Carpenter C., Scaradavou A. Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in hematological malignancies. Proc Natl Acad Sci U S A 2009, 106:19952-19957.
49. Majhail N.S., Brunstein C.G., Wagner J.E. Double umbilical cord blood transplantation. Curr Opin Immunol 2006, 18:571-575.
50. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005, 105:1343-1347.
51. Ballen K.K., Spitzer T.R., Yeap B.Y., et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007, 13:82-89.
52. Brunstein C.G., Barker J.N., Weisdorf D.J., et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007, 110:3064-3070.
53. Verneris M.R., Brunstein C.G., Barker J., et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009, 114:4293-4299.
54. Kang H.J., Yoo K.H., Lee J.W., et al. Double umbilical cord blood transplantation for children and adolescents. Ann Hematol 2010, 89:1035-1044.
55. MacMillan M.L., Weisdorf D.J., Brunstein C.G., et al. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood 2009, 113:2410-2415.
56. Scaradavou A., Smith K.M., Hawke R., et al. Cord blood units with low CD34+ cell viability have a low probability of engraftment after double unit transplantation. Biol Blood Marrow Transplant 2010, 16:500-508.
57. Haspel R.L., Kao G., Yeap B.Y., et al. Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation. Bone Marrow Transplant 2008, 41:523-529.
58. Haspel R.L., Ballen K.K. Double cord blood transplants: filling a niche?. Stem Cell Rev 2006, 2:81-86.
59. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 1978, 4:7-25.
60. Zhang J., Niu C., Ye L., et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003, 425:836-841.
61. Gutman J.A., Turtle C.J., Manley T.J., et al. Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit. Blood 2010, 115:757-765.
62. Robinson S., Niu T., de Lima M., et al. Ex vivo expansion of umbilical cord blood. Cytotherapy 2005, 7:243-250.
63. McNiece I., Jones R., Bearman S.I., et al. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer. Blood 2000, 96:3001-3007.
64. de Lima M., McMannis J., Gee A., et al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant 2008, 41:771-778.
65. Jaroscak J., Goltry K., Smith A., et al. Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell System. Blood 2003, 101:5061-5067.
66. Shpall E.J., Quinones R., Giller R., et al. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant 2002, 8:368-376.
67. Hofmeister C.C., Zhang J., Knight K.L., Le P., Stiff P.J. Ex vivo expansion of umbilical cord blood stem cells for transplantation: growing knowledge from the hematopoietic niche. Bone Marrow Transplant 2007, 39:11-23.
68. Delaney C., Heimfeld S., Brashem-Stein C., Voorhies H., Manger R.L., Bernstein I.D. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010, 16:232-236.
69. Cairo M.S., Rocha V., Gluckman E., Hale G., Wagner J. Alternative allogeneic donor sources for transplantation for childhood diseases: unrelated cord blood and haploidentical family donors. Biol Blood Marrow Transplant 2008, 14:44-53.
70. Gluckman E.G., Roch V.V., Chastang C. Use of cord blood cells for banking and transplant. Oncologist 1997, 2:340-343.
71. Rocha V., Cornish J., Sievers E.L., et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001, 97:2962-2971.
72. Staba S.L., Escolar M.L., Poe M., et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 2004, 350:1960-1969.
73. Bradley M.B., Satwani P., Baldinger L., et al. Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases. Bone Marrow Transplant 2007, 40:621-631.
74. Satwani P., Tallamy B., Jin Z., et al. Reduced intensity conditioning (RIC) allogeneic stem cell transplantation (AlloSCT) in children and adolescent recipients is associated with very low regimen related and non-relapse mortality (NRM): however, chemonaive patients following umbilical cord blood transplant (UCBT) have a higher incidence of primary graft failure (PGF). Biol Blood Marrow Transplant 2009, 15:75-76.
75. Niehues T., Rocha V., Filipovich A.H., et al. Factors affecting lymphocyte subset reconstitution after either related or unrelated cord blood transplantation in children-a Eurocord analysis. Br J Haematol 2001, 114:42-48.
76. Komanduri K.V., St John L.S., de Lima M., et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 2007, 110:4543-4551.
77. Thomson B.G., Robertson K.A., Gowan D., et al. Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation. Blood 2000, 96:2703-2711.
78. Szabolcs P., Cairo M.S. Unrelated umbilical cord blood transplantation and immune reconstitution. Semin Hematol 2010, 47:22-36.
79. Crooks G.M., Weinberg K., Mackall C. Immune reconstitution: from stem cells to lymphocytes. Biol Blood Marrow Transplant 2006, 12:42-46.
80. Talvensaari K., Clave E., Douay C., et al. A broad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation. Blood 2002, 99:1458-1464.
81. Parkman R., Cohen G., Carter S.L., et al. Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol Blood Marrow Transplant 2006, 12:919-927.
82. Freedman J., George D., Jacobson J., et al. Reduced toxicity conditioning (RTC) compared to myeloablative conditioning (MAC) prior to unrelated cord blood transplantation (UCBT) in pediatric recipients was associated with similar but also delayed time to immune reconstitution and a concomitant significant decrease in grade II-IV aGVHD. ASH Annual Meeting Abstracts 2009, 114:2304.
83. Fraser J.K., Cairo M.S., Wagner E.L., et al. Cord Blood Transplantation Study (COBLT): cord blood bank standard operating procedures. J Hematother 1998, 7:521-561.
84. Howard D.H., Meltzer D., Kollman C., et al. Use of cost-effectiveness analysis to determine inventory size for a national cord blood bank. Med Decis Making 2008, 28:243-253.
85. Jenkins G.L., Sugarman J. The importance of cultural considerations in the promotion of ethical research with human biologic material. J Lab Clin Med 2005, 145:118-124.
86. Verlinsky Y., Rechitsky S., Sharapova T., Morris R., Taranissi M., Kuliev A. Preimplantation HLA testing. JAMA 2004, 291:2079-2085.
87. Drukker M., Benvenisty N. The immunogenicity of human embryonic stem-derived cells. Trends Biotechnol 2004, 22:136-141.
88. Takahashi K., Tanabe K., Ohnuki M., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
89. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
90. Feng B., Ng J.H., Heng J.C., Ng H.H. Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. Cell Stem Cell 2009, 4:301-312.
91. Shi Y., Desponts C., Do J.T., Hahm H.S., Scholer H.R., Ding S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell 2008, 3:568-574.
92. Pan C., Lu B., Chen H., Bishop C.E. Reprogramming human fibroblasts using HIV-1 TAT recombinant proteins OCT4, SOX2, KLF4 and c-MYC. Mol Biol Rep 2010, 37:2117-2124.
93. Kaji K., Norrby K., Paca A., Mileikovsky M., Mohseni P., Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009, 458:771-775.
94. van de Ven C., Collins D., Bradley M.B., Morris E., Cairo M.S. The potential of umbilical cord blood multipotent stem cells for nonhematopoietic tissue and cell regeneration. Exp Hematol 2007, 35:1753-1765.
95. Giorgetti A., Montserrat N., Aasen T., et al. Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem Cell 2009, 5:353-357.
96. Takenaka C., Nishishita N., Takada N., Jakt L.M., Kawamata S. Effective generation of iPS cells from CD34+ cord blood cells by inhibition of p53. Exp Hematol 2010, 38:154-162.
97. Kode J.A., Mukherjee S., Joglekar M.V., Hardikar A.A. Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration. Cytotherapy 2009, 11:377-391.
98. Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 2003, 5:485-489.
99. Rebelatto C.K., Aguiar A.M., Moretao M.P., et al. Dissimilar differentiation of mesenchymal stem cells from bone marrow, umbilical cord blood, and adipose tissue. Exp Biol Med (Maywood) 2008, 233:901-913.
100. Javed M.J., Mead L.E., Prater D., et al. Endothelial colony forming cells and mesenchymal stem cells are enriched at different gestational ages in human umbilical cord blood. Pediatr Res 2008, 64:68-73.
101. Ingram D.A., Mead L.E., Tanaka H., et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004, 104:2752-2760.
102. Yoder M.C., Mead L.E., Prater D., et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007, 109:1801-1809.
103. Melero-Martin J.M., Khan Z.A., Picard A., Wu X., Paruchuri S., Bischoff J. In vivo vasculogenic potential of human blood-derived endothelial progenitor cells. Blood 2007, 109:4761-4768.
104. Kogler G., Sensken S., Airey J.A., et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 2004, 200:123-135.
105. Trapp T., Kogler G., El-Khattouti A., et al. Hepatocyte growth factor/c-MET axis-mediated tropism of cord blood-derived unrestricted somatic stem cells for neuronal injury. J Biol Chem 2008, 283:32244-32253.
106. Moelker A.D., Baks T., Wever K.M., et al. Intracoronary delivery of umbilical cord blood derived unrestricted somatic stem cells is not suitable to improve LV function after myocardial infarction in swine. J Mol Cell Cardiol 2007, 42:735-745.
107. Jager M., Degistirici O., Knipper A., Fischer J., Sager M., Krauspe R. Bone healing and migration of cord blood-derived stem cells into a critical size femoral defect after xenotransplantation. J Bone Miner Res 2007, 22:1224-1233.
108. Kim B.O., Tian H., Prasongsukarn K., et al. Cell transplantation improves ventricular function after a myocardial infarction: a preclinical study of human unrestricted somatic stem cells in a porcine model. Circulation 2005, 112. I96-104.
109. Iwasaki H., Kawamoto A., Willwerth C., et al. Therapeutic potential of unrestricted somatic stem cells isolated from placental cord blood for cardiac repair post myocardial infarction. Arterioscler Thromb Vasc Biol 2009, 29:1830-1835.
110. Rabald S., Marx G., Mix B., et al. Cord blood cell therapy alters LV remodeling and cytokine expression but does not improve heart function after myocardial infarction in rats. Cell Physiol Biochem 2008, 21:395-408.
111. Kluth S.M., Buchheiser A., Houben A.P., et al. DLK-1 as a marker to distinguish unrestricted somatic stem cells and mesenchymal stromal cells in cord blood. Stem Cells Dev 2010, 19:1471-1483.
112. Liedtke S., Buchheiser A., Bosch J., et al. The HOX Code as a "biological fingerprint" to distinguish functionally distinct stem cell populations derived from cord blood. Stem Cell Res 2010, 5:40-50.
113. Ebrahimi H., Soleimani M., Kazemi Arababadi M., et al. An in vitro assay to evaluate the immunomodulatory effects of unrestricted somatic stem cells. Iran J Immunol 2010, 7:30-38.
114. Winter M., Wang X.N., Daubener W., et al. Suppression of cellular immunity by cord blood-derived unrestricted somatic stem cells is cytokine-dependent. J Cell Mol Med 2009, 13:2465-2475.
115. Kogler G., Radke T.F., Lefort A., et al. Cytokine production and hematopoiesis supporting activity of cord blood-derived unrestricted somatic stem cells. Exp Hematol 2005, 33:573-583.
116. Chan S.L., Choi M., Wnendt S., et al. Enhanced in vivo homing of uncultured and selectively amplified cord blood CD34+ cells by cotransplantation with cord blood-derived unrestricted somatic stem cells. Stem Cells 2007, 25:529-536.
117. Aktas M., Buchheiser A., Houben A., et al. Good manufacturing practice-grade production of unrestricted somatic stem cell from fresh cord blood. Cytotherapy 2010, 12:338-348.
118. McGuckin C., Jurga M., Ali H., Strbad M., Forraz N. Culture of embryonic-like stem cells from human umbilical cord blood and onward differentiation to neural cells in vitro. Nat Protoc 2008, 3:1046-1055.
119. McGuckin C.P., Forraz N., Baradez M.O., et al. Production of stem cells with embryonic characteristics from human umbilical cord blood. Cell Prolif 2005, 38:245-255.
120. McGuckin C., Forraz N., Baradez M.O., et al. Embryonic-like stem cells from umbilical cord blood and potential for neural modeling. Acta Neurobiol Exp (Wars) 2006, 66:321-329.
121. Habich A., Jurga M., Markiewicz I., Lukomska B., Bany-Laszewicz U., Domanska-Janik K. Early appearance of stem/progenitor cells with neural-like characteristics in human cord blood mononuclear fraction cultured in vitro. Exp Hematol 2006, 34:914-925.
122. Buzanska L., Jurga M., Stachowiak E.K., Stachowiak M.K., Domanska-Janik K. Neural stem-like cell line derived from a nonhematopoietic population of human umbilical cord blood. Stem Cells Dev 2006, 15:391-406.
123. Kucia M., Reca R., Campbell F.R., et al. A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-1(+)Oct-4+ stem cells identified in adult bone marrow. Leukemia 2006, 20:857-869.
124. Kucia M., Halasa M., Wysoczynski M., et al. Morphological and molecular characterization of novel population of CXCR4+ SSEA-4+ Oct-4+ very small embryonic-like cells purified from human cord blood: preliminary report. Leukemia 2007, 21:297-303.
125. Shin D.M., Zuba-Surma E.K., Wu W., et al. Novel epigenetic mechanisms that control pluripotency and quiescence of adult bone marrow-derived Oct4(+) very small embryonic-like stem cells. Leukemia 2009, 23:2042-2051.
126. Paczkowska E., Kucia M., Koziarska D., et al. Clinical evidence that very small embryonic-like stem cells are mobilized into peripheral blood in patients after stroke. Stroke 2009, 40:1237-1244.
127. Wojakowski W., Tendera M., Kucia M., et al. Mobilization of bone marrow-derived Oct-4+ SSEA-4+ very small embryonic-like stem cells in patients with acute myocardial infarction. J Am Coll Cardiol 2009, 53:1-9.
128. Kogler G., Sensken S., Wernet P. Comparative generation and characterization of pluripotent unrestricted somatic stem cells with mesenchymal stem cells from human cord blood. Exp Hematol 2006, 34:1589-1595.
129. Kang K.S., Kim S.W., Oh Y.H., et al. A 37-year-old spinal cord-injured female patient, transplanted of multipotent stem cells from human UC blood, with improved sensory perception and mobility, both functionally and morphologically: a case study. Cytotherapy 2005, 7:368-373.
130. Valbonesi M., Giannini G., Migliori F., Dalla Costa R., Dejana A.M. Cord blood (CB) stem cells for wound repair. Preliminary report of 2 cases. Transfus Apher Sci 2004, 30:153-156.
131. Chen J., Sanberg P.R., Li Y., et al. Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke 2001, 32:2682-2688.
132. Jin K., Sun Y., Xie L., et al. Comparison of ischemia-directed migration of neural precursor cells after intrastriatal, intraventricular, or intravenous transplantation in the rat. Neurobiol Dis 2005, 18:366-374.
133. Kelly S., Bliss T.M., Shah A.K., et al. Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex. Proc Natl Acad Sci U S A 2004, 101:11839-11844.
134. Willing A.E., Lixian J., Milliken M., et al. Intravenous versus intrastriatal cord blood administration in a rodent model of stroke. J Neurosci Res 2003, 73:296-307.
135. Borlongan C.V., Evans A., Yu G., Hess D.C. Limitations of intravenous human bone marrow CD133+ cell grafts in stroke rats. Brain Res 2005, 1048:116-122.
136. Vendrame M., Cassady J., Newcomb J., et al. Infusion of human umbilical cord blood cells in a rat model of stroke dose-dependently rescues behavioral deficits and reduces infarct volume. Stroke 2004, 35:2390-2395.
137. Hill W.D., Hess D.C., Martin-Studdard A., et al. SDF-1 (CXCL12) is upregulated in the ischemic penumbra following stroke: association with bone marrow cell homing to injury. J Neuropathol Exp Neurol 2004, 63:84-96.
138. Newman M.B., Willing A.E., Manresa J.J., Davis-Sanberg C., Sanberg P.R. Stroke-induced migration of human umbilical cord blood cells: time course and cytokines. Stem Cells Dev 2005, 14:576-586.
139. Borlongan C.V., Hadman M., Sanberg C.D., Sanberg P.R. Central nervous system entry of peripherally injected umbilical cord blood cells is not required for neuroprotection in stroke. Stroke 2004, 35:2385-2389.
140. Newcomb J.D., Ajmo C.T., Sanberg C.D., Sanberg P.R., Pennypacker K.R., Willing A.E. Timing of cord blood treatment after experimental stroke determines therapeutic efficacy. Cell Transplant 2006, 15:213-223.
141. Shen L.H., Li Y., Chen J., et al. Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke. J Cereb Blood Flow Metab 2007, 27:6-13.
142. Xiao J., Nan Z., Motooka Y., Low W.C. Transplantation of a novel cell line population of umbilical cord blood stem cells ameliorates neurological deficits associated with ischemic brain injury. Stem Cells Dev 2005, 14:722-733.
143. Taguchi A., Soma T., Tanaka H., et al. Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest 2004, 114:330-338.
144. Vendrame M., Gemma C., de Mesquita D., et al. Anti-inflammatory effects of human cord blood cells in a rat model of stroke. Stem Cells Dev 2005, 14:595-604.
145. Jiang L., Womble T.A., Saporta S., et al. Human umbilical cord blood cells decrease microglial survival in vitro. Stem Cells Dev 2010, 19:221-228.
146. Vendrame M., Gemma C., Pennypacker K.R., et al. Cord blood rescues stroke-induced changes in splenocyte phenotype and function. Exp Neurol 2006, 199:191-200.
147. Garbuzova-Davis S., Sanberg C.D., Kuzmin-Nichols N., et al. Human umbilical cord blood treatment in a mouse model of ALS: optimization of cell dose. PLoS One 2008, 3:e2494.
148. Imitola J., Raddassi K., Park K.I., et al. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci U S A 2004, 101:18117-18122.
149. Ende N., Chen R. Human umbilical cord blood cells ameliorate Huntington's disease in transgenic mice. J Med 2001, 32:231-240.
150. Garbuzova-Davis S., Willing A.E., Zigova T., et al. Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation. J Hematother Stem Cell Res 2003, 12:255-270.
151. Park K.I., Hack M.A., Ourednik J., et al. Acute injury directs the migration, proliferation, and differentiation of solid organ stem cells: evidence from the effect of hypoxia-ischemia in the CNS on clonal "reporter" neural stem cells. Exp Neurol 2006, 199:156-178.
152. Meier C., Middelanis J., Wasielewski B., et al. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. Pediatr Res 2006, 59:244-249.
153. Belmadani A., Tran P.B., Ren D., Miller R.J. Chemokines regulate the migration of neural progenitors to sites of neuroinflammation. J Neurosci 2006, 26:3182-3191.
154. Jiang L., Newman M., Saporta S., et al. MIP-1alpha and MCP-1 induce migration of human umbilical cord blood cells in models of stroke. Curr Neurovasc Res 2008, 5:118-124.
155. Bliss T.M., Kelly S., Shah A.K., et al. Transplantation of hNT neurons into the ischemic cortex: cell survival and effect on sensorimotor behavior. J Neurosci Res 2006, 83:1004-1014.
156. Mollmann H., Nef H., Elsasser A., Hamm C. Stem cells in myocardial infarction: from bench to bedside. Heart 2009, 95:508-514.
157. Ma N., Ladilov Y., Kaminski A., et al. Umbilical cord blood cell transplantation for myocardial regeneration. Transplant Proc 2006, 38:771-773.
158. Henning R.J., Abu-Ali H., Balis J.U., Morgan M.B., Willing A.E., Sanberg P.R. Human umbilical cord blood mononuclear cells for the treatment of acute myocardial infarction. Cell Transplant 2004, 13:729-739.
159. Hirata Y., Sata M., Motomura N., et al. Human umbilical cord blood cells improve cardiac function after myocardial infarction. Biochem Biophys Res Commun 2005, 327:609-614.
160. Leor J., Guetta E., Feinberg M.S., et al. Human umbilical cord blood-derived CD133+ cells enhance function and repair of the infarcted myocardium. Stem Cells 2006, 24:772-780.
161. Ma N., Stamm C., Kaminski A., et al. Human cord blood cells induce angiogenesis following myocardial infarction in NOD/scid-mice. Cardiovasc Res 2005, 66:45-54.
162. Henning R.J., Burgos J.D., Vasko M., et al. Human cord blood cells and myocardial infarction: effect of dose and route of administration on infarct size. Cell Transplant 2007, 16:907-917.
163. Ghodsizad A., Niehaus M., Kogler G., et al. Transplanted human cord blood-derived unrestricted somatic stem cells improve left-ventricular function and prevent left-ventricular dilation and scar formation after acute myocardial infarction. Heart 2009, 95:27-35.
164. Bartunek J., Wijns W., Heyndrickx G.R., Vanderheyden M. Timing of intracoronary bone-marrow-derived stem cell transplantation after ST-elevation myocardial infarction. Nat Clin Pract Cardiovasc Med 2006, 3(suppl 1):S52-S56.
165. Haider H., Ashraf M. Strategies to promote donor cell survival: combining preconditioning approach with stem cell transplantation. J Mol Cell Cardiol 2008, 45:554-566.
166. Park K.I., Teng Y.D., Snyder E.Y. The injured brain interacts reciprocally with neural stem cells supported by scaffolds to reconstitute lost tissue. Nat Biotechnol 2002, 20:1111-1117.